Results 81 to 90 of about 91,755 (270)

Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Spread: A Systematic Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris   +4 more
wiley   +1 more source

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

open access: yesCancer Medicine
Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in ...
Ken Kato   +21 more
doaj   +1 more source

Risk Factors for Osteoradionecrosis After Head and Neck Radiotherapy: A Systematic Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction Although intensity‐modulated radiotherapy (IMRT) has led to a significant reduction in mandibular osteoradionecrosis (ORN) rates, head‐and‐neck radiotherapy (RT) is rapidly evolving—with increasing use of altered schedules and with novel systemic regimens including immune checkpoint inhibitors (ICI).
Jennifer Le Guevelou   +5 more
wiley   +1 more source

Clinical utility of nivolumab in the treatment of advanced melanoma

open access: yes, 2016
Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that ...
Yang J, Carvajal RD, Asmar R
core  

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

open access: yesOncoImmunology, 2017
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response.
Courèche-Guillaume Kaderbhai   +17 more
doaj   +1 more source

Corneal ulceration associated with Nivolumab use

open access: yesAmerican Journal of Ophthalmology Case Reports, 2019
Purpose: To describe a case of corneal ulceration associated with Nivolumab use. Observations: An 80-year-old woman treated with Nivolumab for metastatic melanoma developed an intractable corneal ulcer in her left eye, refractory to all therapies ...
Jack S. Parker   +4 more
doaj   +1 more source

Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index ...
Phoebe L. Sault   +3 more
wiley   +1 more source

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

open access: yesHepatology Communications, 2020
Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared ...
Won‐Mook Choi   +12 more
doaj   +1 more source

Specialist Palliative Care and Potentially Avoidable Acute Care at the End of Life for Head and Neck Cancer in the Immunotherapy Era: Population‐Based Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The role of specialist palliative care (SPC) alongside immunotherapy in head and neck cancer (HNC) is unclear. Methods This retrospective population‐based cohort study included adults with HNC who died in 2013–2021 in Alberta, Canada.
Rui Fu   +12 more
wiley   +1 more source

A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency

open access: yesRespiratory Medicine Case Reports, 2019
One of the novel PD-1 antibodies/immune checkpoint inhibitors, nivolumab is reported to be associated with a wide range of immune-related adverse events (irAEs). We hereby report a case of isolated adrenocorticotropic hormone (ACTH) deficiency developing
Yozo Sato   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy